ZYBERNO
Stock Report
Updated Sep 1, 2026

CervoMed Inc. (CRVO)

Healthcare • NASDAQ

$2.63

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
25.0/100
POOR BUSINESS
CervoMed Inc. (CRVO) scores 25/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-156.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-9,407.0%)
Return on Capital (Capital Efficiency):CRITICAL (-4,696.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CervoMed Inc. (CRVO) stock report — Zyberno Score 25/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.63
Market Cap:$26.94M

Valuation Multiples (3)

P/B Ratio:1.17x
P/S Ratio:81.33x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$4.48M

Price Action & Momentum (3)

Momentum Percentile:8 / 100
% of 52-Week High:24.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-128.3%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (3)

Operating Margin Ttm:-9,407.0%
Net Margin Ttm:-9,160.9%
Ebitda Margin:-9,407.0%

TTM Performance (2)

Operating Margin Ttm:-9,407.0%
Net Margin Ttm:-9,160.9%

Yield Metrics (2)

Earnings Yield:-$117.95
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-100.0%
Latest Earnings Filed:2024-11-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:8.57x
Quick Ratio:8.57x
Cash Ratio:7.41x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:22,960,297.00
Cash And Cash Equivalents:22,462,577.00
Long Term Debt:$0.00
Net Debt:-$22.46M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $331.30K
Linear Growth: -50.0%
📊 Click to view full CRVO Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$31.16M

Bottom Line Performance (3)

-$30.35M
Income Before Tax:$0.00
Ebitda Ttm:-31,164,793.00

Operating Expenses (5)

Operating Expenses:31,496,088.00
R And D Expense:21,327,840.00
Sga Expense:10,168,248.00
Income Tax Expense:-$843.89K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-9,407.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$25.99M
Current Assets:$25.99M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,032,174.00
Current Liabilities:3,032,174.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$22.96M
Retained Earnings:-$112.23M
Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:687,111.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:362,275.00
C. Cash Flow Analysis

Operating Activities (2)

-$27.57M$0.00

Investment Activities (1)

Investing Cash Flow:$7.71M

Financing Activities (3)

Financing Cash Flow:$13.80K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (2)

EPS (Basic TTM):-3.22
Earnings Per Share Ttm:-$2.96

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.03
Operating Cash Flow Per Share:-$2.29

Book Value & Capital (2)

Book Value Per Share:$2.24
Cash Per Share:2.19

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:0.01x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:757.02
Cash Conversion Cycle:-2,755.02
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):1.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:CRVO
Company Name:CervoMed Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:10.24M
Shares Outstanding Basic:10.24M
Shares Outstanding Diluted:8.70M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 09:21:32 UTC
Data Timestamp:2026-08-20T23:19:16.077021
Scroll to Top